Migratory pulmonary infiltrates in a patient with rheumatoid arthritis

Meharndru, S.; Smith, R. L.; Sidhu, G. S.; Cassai, N.; Aranda, C. P.
May 2002
Thorax;May2002, Vol. 57 Issue 5, p465
Academic Journal
The case history is described of an elderly man with rheumatoid arthritis receiving treatment with sulfasalazine and the cyclooxygenase-2 inhibitor celecoxib who presented with severe shortness of breath, cough, and decreased exercise tolerance. The chest radiograph showed unilateral alveolo-interstitial infiltrates and a biopsy specimen of the lung parenchyma showed changes consistent with acute eosinophilic pneumonia. Antibiotic treatment was unsuccessful, but treatment with steroids and discontinuation of sulfasalazine and celecoxib resulted in a marked clinical improvement confirmed by arterial blood gas analysis. The condition may hove developed as an adverse reaction either to sulfasalazine or to celecoxib, although hypersensitivity to the latter has not previously been reported.


Related Articles

  • Celecoxib best value in high-risk patients with RA.  // PharmacoEconomics & Outcomes News;12/3/2005, Issue 492, p7 

    The article presents information on the research conducted regarding the cost effectiveness of celecoxib for the treatment of rheumatoid arthritis (RA) in The Netherlands. The researchers used a model in comparing the cost effectiveness of celecoxib with the common practice for the management of...

  • Celecoxib: A Review of its Use in the Management of Arthritis and Acute Pain. Frampton, James E.; Keating, Gillian M. // Drugs;2007, Vol. 67 Issue 16, p2433 

    Celecoxib (Celebrex®), the first cyclo-oxygenase (COX) 2-selective inhibitor (coxib) to be introduced into clinical practice, has been available for almost a decade. It is approved in one or more countries worldwide for the relief of the signs and symptoms of osteoarthritis (OA), rheumatoid...

  • Understanding COX-2 Inhibitors Part II: Applications for Practice. Spolarich, Ann Eshenaur // Access;Apr2002, Vol. 16 Issue 4, p45 

    Focuses on the pharmacology of the COX-2 inhibitors in the U.S. Cumulative incidence of gastrointestinal tract (GI) ulceration; Reduction of the symptoms of rheumatoid arthritis; History of GI ulceration.

  • Comparing celecoxib with traditional nonsteroidal anti-inflammatory drugs. Johnson, Melissa; Seaton, Terry // Journal of Family Practice;Feb2003, Vol. 52 Issue 2, p96 

    The article presents a study comparing the efficacy, safety and tolerability of celecoxib with other nonsteroidal anti-inflammatory drugs (NSAID) for treating osteoarthritis or rheumatoid arthritis. Celecoxib was developed to provide symptom relief without the NSAID-associated gastrointestinal...

  • Cardiorenal effects of celecoxib as compared with the nonsteroidal anti-inflammatory drugs diclofenac and ibuprofen. Whelton, A.; Lefkowith, J. L.; West, C. R.; Verburg, K. M. // Kidney International;Oct2006, Vol. 70 Issue 8, p1495 

    The cardiorenal safety database from the Celecoxib Long-term Arthritis Safety Study (CLASS) was analyzed to examine whether supratherapeutic doses of celecoxib are associated with decreased renal function and blood pressure (BP) effects compared with standard doses of diclofenac and ibuprofen in...

  • Celecoxib, a cyclooxygenase-2 inhibitor, improved upper gastrointestinal lesions in rheumatoid arthritis patients as assessed by endoscopic evaluation. Tsuji, Shigeyoshi; Miyoshi, Hirofumi; Tomita, Tetsuya; Nakase, Takanobu; Hamada, Masayuki; Oomae, Takahiro; Tsumoto, Chikako; Hirata, Yoshimasa; Iguchi, Munetaka; Edogawa, Shoko; Kawai, Hideo; Yoshikawa, Hideki // Modern Rheumatology (Springer Science & Business Media B.V.);Jun2012, Vol. 22 Issue 3, p353 

    We prospectively evaluated the effects of celecoxib (CEL) on the gastrointestinal (GI) tract of rheumatoid arthritis (RA) patients with endoscopically identified GI mucosal injury after therapeutic switching from the long-term use of traditional nonsteroidal anti-inflammatory drugs (NSAIDs)....

  • COX-2s and heart disease.  // GP: General Practitioner;1/27/2003, p2 

    Reports on the benefit of COX-2 inhibitors to patients with heart diseases as well as arthritis. Endothelial functions improved by the inhibitor celecobix; Other therapeutic uses of celecobix.

  • Celecoxib dilates guinea-pig coronaries and rat aortic rings and amplifies NO/cGMP signaling by PDE5 inhibition. Klein, Thomas; Eltze, Manfrid; Grebe, Thomas; Hatzelmann, Armin; K�mhoff, Martin // Cardiovascular Research;Jul2007, Vol. 75 Issue 2, p390 

    Abstract: Objective : Celecoxib carries a smaller cardiovascular risk for myocardial infarction and hypertension than other cyclooxygenase-2 (COX-2)-selective non-steroidal anti-inflammatory drugs NSAIDs (�coxibs�) and may ameliorate endothelial dysfunction. We aimed to determine which...

  • Effects of acetylsalicylic acid and celecoxib on the N-nitrosodiethylamine induced carcinogenesis in rat liver and esophagus. L. Bolieva; F. Dzhioev; S. Kakabadze // Bulletin of Experimental Biology & Medicine;Jan2007, Vol. 143 Issue 1, p87 

    Abstract  The effects of nonsteroid antiinflammatory drugs (acetylsalicylic acid and celecoxib) on N-nitrosodiethylamine-induced carcinogenesis in the liver and esophagus were studied in rats. The inhibitory effect of celecoxib on carcinogenesis was more pronounced (in comparison with...


Read the Article


Sign out of this library

Other Topics